Non Small Cell Lung Cancer - Immunotherapy - PD-L1 negative + TMB-L + STING overexpression

Association details:

Biomarker:	PD-L1 negative + TMB-L + STING overexpression
Cancer:	Non Small Cell Lung Cancer
Drug Class:	Immunotherapy
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

ASCO 2023

Title:

Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).

Published date:

05/25/2023

Excerpt:

Here we report the role of CGS pathway in NSCLC tumors that are both PDL1-negative and TMB-Low....Median overall survival (OS) was 21.1 months in the STING-high cohort (n=200) vs 11.9 months in the STING-low cohort (n=199) in IO treated pts (HR = 0.62, p<0.000.1)

DOI:

10.1200/JCO.2023.41.16_suppl.9120